Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | GCGR | P47871 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.48 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.47 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PTPRC | P08575 | 1/20 | 0.44 |
| ▸ | S100A4 | P26447 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14809788 | 0.87 | CYP19A1 (0.52) | MAPK14GCGRALDH1A1HIF1ACYP19A1 | |
| SCHEMBL6573092 | 0.83 | PTGS2 (0.55) | ALDH1A1HIF1ACYP19A1NPC1MAPT | |
| SCHEMBL2652363 | 0.83 | ALDH1A1 (0.47) | MAPK14GCGRALDH1A1HIF1ANPC1 | |
| SCHEMBL4910527 | 0.82 | ALDH1A1 (0.67) | ALDH1A1HIF1AMAPTPTPRCS100A4 | |
| SCHEMBL2651516 | 0.81 | CYP19A1 (0.54) | ALDH1A1HIF1ACYP19A1CYP11B1CYP11B2 | |
| SCHEMBL2648687 | 0.81 | ALDH1A1 (0.49) | MAPK14GCGRALDH1A1HIF1ANPC1 | |
| SCHEMBL429611 | 0.80 | ALDH1A1 (0.55) | MAPK14GCGRALDH1A1CYP19A1CYP11B1 | |
| SCHEMBL9568408 | 0.80 | ALDH1A1 (0.55) | ALDH1A1HIF1ANPC1PDE7AMAPT | |
| SCHEMBL1931406 | 0.80 | ALDH1A1 (0.51) | ALDH1A1HIF1AMAPTPTPRCS100A4 | |
| SCHEMBL2651288 | 0.80 | ALDH1A1 (0.47) | MAPK14GCGRALDH1A1HIF1ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1294133-C | Imidazo-pyrimidine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME (GB) | 2007-01-10 | — | — | CN | disclosed |
| EP-1343788-B1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2005-11-23 | — | — | EP | disclosed |
| US-6960598-B2 | (1,8) naphthyridines as gaba ligands, their pharmaceutical compositions and uses | MERCK SHARP & DOHME LTD. | 2005-11-01 | — | — | US | disclosed |
| US-6936608-B2 | Imidazo-triazine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. | 2005-08-30 | — | — | US | disclosed |
| EP-1381606-B1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2005-07-20 | — | — | EP | disclosed |
| US-6900215-B2 | For therapy of disorders of central nervous system, including anxiety, convulsions and cognitive disorders | MERCK SHARP & DOHME LTD. (GB) | 2005-05-31 | — | — | US | disclosed |
| US-20040171633-A1 | (1, 8) naphthyridines as gaba ligands, their pharmaceutical compositions and uses | MERCK SHARP & DOHME LTD. (GB) | 2004-09-02 | — | — | US | disclosed |
| CN-1498218-A | Imidazo-pyrimidine derivatives as GABA receptor ligands | Ĭ�ˡ�����-��ķ��˾ | 2004-05-19 | — | — | CN | disclosed |
| US-20040023964-A1 | Imidazo-triazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2004-02-05 | — | — | US | disclosed |
| EP-1381606-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2004-01-21 | — | — | EP | disclosed |
| EP-1343788-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2003-09-17 | — | — | EP | disclosed |
| WO-2003006464-A1 | (1,8) NAPHTHYRIDINES AS GABA LIGANDS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES | MERCK SHARP & DOHME LIMITED (GB) | 2003-01-23 | — | — | WO | disclosed |
| US-20020193385-A1 | Imidazo-pyrimidine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2002-12-19 | — | — | US | disclosed |
| WO-2002074772-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074773-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002038568-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193385-A1 | Imidazo-pyrimidine derivatives as ligands for gaba receptors | GABRA3, GABRA1, GABRA2 | MAPK14 2886/4885GCGR 572/4885ALDH1A1 404/4885 |
| US-20040023964-A1 | Imidazo-triazine derivatives as ligands for gaba receptors | GABRA2, GABRA5, GABRA1 | MAPK14 2598/4885GCGR 914/4885ALDH1A1 646/4885 |
| US-20040171633-A1 | (1, 8) naphthyridines as gaba ligands, their pharmaceutical compositions and uses | GABRA1, GABRA4, GABRA6 | MAPK14 4058/4885GCGR 700/4885ALDH1A1 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.